ValiRx (LSE:VAL) reported additional annual cost savings of £42,500 through salary reductions and changes to its advisory board structure. At the same time, the company continues to develop its collaboration with Dominion Biotech, working together to co-develop and commercialise patient-derived cell models and related research programmes.
The company has also expanded its research pipeline through several new initiatives. ValiRx signed a preclinical evaluation agreement with McGill University and IRICoR, while progressing a fast-track orphan disease programme. It also launched ValiRx Animal Health Ltd, a new subsidiary focused on commercialising oncology-related assets within the veterinary sector, where the company is already engaging with specialist clinics and potential funding partners.
Further development work has continued across its research portfolio. ValiRx advanced its CytoLytix oncolytic peptide programme with a new in-house formulation, supported by research data generated with partners ScreeIn3D and Bioreparia, and plans to file a related patent application in April 2026. The company is also collaborating with Cellomatics to develop immune-oncology co-culture models using colorectal cancer cells provided by Inaphaea.
In addition, ValiRx has strengthened its academic network through grant-backed collaborations with the University of Nottingham and the Open University, focusing on peptide delivery systems and prostate cancer targeting technologies. Work is also progressing on validation of the VAL201 2.0 construct and additional patent filings. These initiatives are intended to support future external investment and expand commercial opportunities across both human and veterinary oncology markets.
ValiRx’s outlook remains constrained by challenging financial fundamentals, including ongoing losses and reliance on external funding. Technical indicators suggest a broadly bearish share price trend, although some potential for upward movement remains. Valuation metrics are also limited due to the company’s negative price-to-earnings ratio and the absence of dividend support.
More about ValiRx plc
ValiRx plc is a UK-based life sciences company focused on developing early-stage cancer therapies and women’s health treatments. Using a translational development model, the company aims to advance novel drug candidates from preclinical research toward clinic-ready and investor-ready assets. ValiRx operates through a network of subsidiaries and academic and commercial partnerships designed to accelerate drug development in oncology and related therapeutic areas. The company is listed on London’s AIM market under the ticker VAL.
Leave a Reply